The impact of the COVID-19 lockdown on HIV care in 65 South African primary care clinics: an interrupted time series analysis.
Adolescent
Adult
Ambulatory Care Facilities
Anti-HIV Agents
/ therapeutic use
Antiretroviral Therapy, Highly Active
COVID-19
/ prevention & control
Child
Child, Preschool
Female
HIV Infections
/ diagnosis
Humans
Infant
Infant, Newborn
Interrupted Time Series Analysis
Male
Mass Screening
/ statistics & numerical data
Middle Aged
Primary Health Care
/ statistics & numerical data
Public Health Surveillance
SARS-CoV-2
South Africa
Young Adult
Journal
The lancet. HIV
ISSN: 2352-3018
Titre abrégé: Lancet HIV
Pays: Netherlands
ID NLM: 101645355
Informations de publication
Date de publication:
03 2021
03 2021
Historique:
received:
20
10
2020
revised:
11
12
2020
accepted:
17
12
2020
pubmed:
8
2
2021
medline:
12
3
2021
entrez:
7
2
2021
Statut:
ppublish
Résumé
The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and treatment in KwaZulu-Natal, South Africa, where 1·7 million people are living with HIV. In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care clinics in KwaZulu-Natal province, South Africa. We included data from people testing for HIV, initiating antiretroviral therapy (ART), and collecting ART at participating clinics during the study period, with no age restrictions. We used descriptive statistics to summarise demographic and clinical data, and present crude summaries of the main outcomes of numbers of HIV tests per month, ART initiations per week, and ART collection visits per week, before and after the national lockdown that began on March 27, 2020. We used Poisson segmented regression models to estimate the immediate impact of the lockdown on these outcomes, as well as post-lockdown trends. Between Jan 1, 2018, and July 31, 2020, we recorded 1 315 439 HIV tests. Between Jan 1, 2018, and June 15, 2020, we recorded 71 142 ART initiations and 2 319 992 ART collection visits. We recorded a median of 41 926 HIV tests per month before lockdown (January, 2018, to March, 2020; IQR 37 838-51 069) and a median of 38 911 HIV tests per month after lockdown (April, 2020, to July, 2020; IQR 32 699-42 756). In the Poisson regression model, taking into account long-term trends, lockdown was associated with an estimated 47·6% decrease in HIV testing in April, 2020 (incidence rate ratio [IRR] 0·524, 95% CI 0·446-0·615). ART initiations decreased from a median of 571 per week before lockdown (IQR 498-678), to 375 per week after lockdown (331-399), with an estimated 46·2% decrease in the Poisson regression model in the first week of lockdown (March 30, 2020, to April 5, 2020; IRR 0·538, 0·459-0·630). There was no marked change in the number of ART collection visits (median 18 519 visits per week before lockdown [IQR 17 074-19 922] vs 17 863 visits per week after lockdown [17 509-18 995]; estimated effect in the first week of lockdown IRR 0·932, 95% CI 0·794-1·093). As restrictions eased, HIV testing and ART initiations gradually improved towards pre-lockdown levels (slope change 1·183/month, 95% CI 1·113-1·256 for HIV testing; 1·156/month, 1·085-1·230 for ART initiations). ART provision was generally maintained during the 2020 COVID-19 lockdown, but HIV testing and ART initiations were heavily impacted. Strategies to increase testing and treatment initiation should be implemented. Wellcome Trust, Africa Oxford Initiative.
Sections du résumé
BACKGROUND
The effect of the COVID-19 pandemic on HIV outcomes in low-income and middle-income countries is poorly described. We aimed to measure the impact of the 2020 national COVID-19 lockdown on HIV testing and treatment in KwaZulu-Natal, South Africa, where 1·7 million people are living with HIV.
METHODS
In this interrupted time series analysis, we analysed anonymised programmatic data from 65 primary care clinics in KwaZulu-Natal province, South Africa. We included data from people testing for HIV, initiating antiretroviral therapy (ART), and collecting ART at participating clinics during the study period, with no age restrictions. We used descriptive statistics to summarise demographic and clinical data, and present crude summaries of the main outcomes of numbers of HIV tests per month, ART initiations per week, and ART collection visits per week, before and after the national lockdown that began on March 27, 2020. We used Poisson segmented regression models to estimate the immediate impact of the lockdown on these outcomes, as well as post-lockdown trends.
FINDINGS
Between Jan 1, 2018, and July 31, 2020, we recorded 1 315 439 HIV tests. Between Jan 1, 2018, and June 15, 2020, we recorded 71 142 ART initiations and 2 319 992 ART collection visits. We recorded a median of 41 926 HIV tests per month before lockdown (January, 2018, to March, 2020; IQR 37 838-51 069) and a median of 38 911 HIV tests per month after lockdown (April, 2020, to July, 2020; IQR 32 699-42 756). In the Poisson regression model, taking into account long-term trends, lockdown was associated with an estimated 47·6% decrease in HIV testing in April, 2020 (incidence rate ratio [IRR] 0·524, 95% CI 0·446-0·615). ART initiations decreased from a median of 571 per week before lockdown (IQR 498-678), to 375 per week after lockdown (331-399), with an estimated 46·2% decrease in the Poisson regression model in the first week of lockdown (March 30, 2020, to April 5, 2020; IRR 0·538, 0·459-0·630). There was no marked change in the number of ART collection visits (median 18 519 visits per week before lockdown [IQR 17 074-19 922] vs 17 863 visits per week after lockdown [17 509-18 995]; estimated effect in the first week of lockdown IRR 0·932, 95% CI 0·794-1·093). As restrictions eased, HIV testing and ART initiations gradually improved towards pre-lockdown levels (slope change 1·183/month, 95% CI 1·113-1·256 for HIV testing; 1·156/month, 1·085-1·230 for ART initiations).
INTERPRETATION
ART provision was generally maintained during the 2020 COVID-19 lockdown, but HIV testing and ART initiations were heavily impacted. Strategies to increase testing and treatment initiation should be implemented.
FUNDING
Wellcome Trust, Africa Oxford Initiative.
Identifiants
pubmed: 33549166
pii: S2352-3018(20)30359-3
doi: 10.1016/S2352-3018(20)30359-3
pmc: PMC8011055
pii:
doi:
Substances chimiques
Anti-HIV Agents
0
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e158-e165Subventions
Organisme : Medical Research Council
ID : MR/R010161/1
Pays : United Kingdom
Organisme : Wellcome Trust
Pays : United Kingdom
Informations de copyright
Copyright © 2021 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.
Références
Lancet Glob Health. 2020 Oct;8(10):e1305-e1315
pubmed: 32971053
J Int AIDS Soc. 2014 Apr 28;17:18908
pubmed: 24780511
BMJ Open. 2020 May 15;10(5):e035412
pubmed: 32414827
BMJ Glob Health. 2020 Oct;5(10):
pubmed: 33028699
Lancet Glob Health. 2015 Jan;3(1):e52-61
pubmed: 25539970
AIDS Behav. 2020 Nov;24(11):3006-3009
pubmed: 32451939
Clin Infect Dis. 2021 Jan 27;72(2):327-331
pubmed: 33501963
Lancet HIV. 2020 May;7(5):e308-e309
pubmed: 32272084
Lancet Glob Health. 2020 Sep;8(9):e1132-e1141
pubmed: 32673577
BMJ Open. 2020 Oct 5;10(10):e043763
pubmed: 33020109
Lancet HIV. 2020 Nov;7(11):e735
pubmed: 32758479
J Int AIDS Soc. 2020 Aug;23(8):e25587
pubmed: 32767707
J Int AIDS Soc. 2020 May;23(5):e25503
pubmed: 32378345
Lancet. 2020 May 23;395(10237):1611
pubmed: 32405104
Science. 2020 Jul 24;369(6502):366-368
pubmed: 32703860
Lancet. 2020 May 30;395(10238):1687-1688
pubmed: 32539939
Int J Epidemiol. 2017 Feb 1;46(1):348-355
pubmed: 27283160
Gates Open Res. 2020 Jul 29;4:117
pubmed: 32954217
AIDS Behav. 2020 Nov;24(11):3010-3013
pubmed: 32488552
EClinicalMedicine. 2020 Apr 22;22:100342
pubmed: 32322805
S Afr Med J. 2020 Jun 19;110(8):724-726
pubmed: 32880296
Clin Infect Dis. 2021 Jun 1;72(11):e828-e834
pubmed: 33045723
Lancet HIV. 2020 Sep;7(9):e629-e640
pubmed: 32771089